However, the tumor-killing functions of these tumor-reactive CD8+ T cells were not assessed and whether this personalized DC-based vaccine strategy is capable of improving patient cancer-free survival remains to be assessed in future clinical trials. This evidence concerns the gene CD8A and neoplasm.